Last week saw a large number of broker notes hitting the wires once again. Three buy ratings that caught my eye are summarised below.
Here’s why brokers think investors ought to buy them next week:
A2 Milk Company Ltd (ASX: A2M)
According to a note out of UBS, its analysts have retained their buy rating on this infant formula and fresh milk company’s shares but reduced their price target on them to NZ$16.20 (A$15.11). Although it expects margins to fall as it increases its marketing investment to win market share, it expects margins to recover from FY 2023. And with the investment likely to make a2 Milk Company a bigger and profitable company, they appear to believe it is worth sticking with it. I agree with UBS on this one and see it as a good buy and hold option.
CSL Limited (ASX: CSL)
A note of Morgan Stanley reveals that its analysts have upgraded this biotherapeutics company’s shares to an overweight rating and lifted the price target on them to $251.00. According to the note, the broker believes that the tight immunoglobulin market means that CSL’s supply increase is being absorbed. This could mean there is upside risk to its earnings guidance in FY 2020. And while it sees the potential for disruption in the industry in the future, it doesn’t believe this will be for a few years. I agree with Morgan Stanley and would class its shares as a buy.
Nufarm Limited (ASX: NUF)
Equity analysts at Credit Suisse have retained their outperform rating on this agricultural chemicals company’s shares and lifted the price target on them to $8.30. According to the note, the broker was pleased with Nufarm’s decision to offload its South American business at a good price. It notes that this has removed financing risk and expects the market to appreciate its lower leverage. In addition to this, the broker has previously spoken very positively about the prospects of its omega-3 canola oil business. I agree that Nufarm is a much more attractive option for investors now its balance sheet is stronger.
And if you're looking for more options then check out these buy-rated shares.
You’re invited! For a limited time, The Motley Fool Australia is giving away an urgent new investment report detailing our 3 TOP BLUE CHIP SHARES to own in 2019.
So if you like trustworthy, stable, high-performing companies that pay fat fully franked dividends – we’ve got you covered!
Stock #1 is a beloved old Australian company turning its attention to high-margin businesses... and rapidly returning cash to shareholders with its hefty dividend...
While Stock #2 is an online powerhouse that’s rapidly gaining market share all around the globe... poised for years (or even decades) of tremendous growth...
Even better, Stock #3 offers a whopping 6.5% grossed-up dividend! Which beats the rates on term deposits right out of the water – and offers the potential for capital gains, too.
You can discover all three shares inside our new report right now. To scoop up your FREE copy, simply click the link below right now. But you will want to hurry – this free report is available for a LIMITED TIME ONLY!
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia owns shares of A2 Milk. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.